CBRS reported earnings on June 23 and walked away with a wave of analyst upgrades — yet the borrow market remains completely frozen, creating the week's central tension.
The Street's response to results was unambiguous. Multiple firms raised price targets the day after the print. UBS lifted its target from $300 to $320, maintaining Buy. Morgan Stanley moved from $250 to $273 on an Overweight. Wedbush nudged to $280 from $270, keeping Outperform. Needham and Rosenblatt held firm at $300 Buy. The consensus mean target now sits at $299, implying roughly 32% upside to Tuesday's close of $226.72. The bull case centres on Cerebras's record-breaking inference speeds and its positioning in the fast-growing AI compute market. Bears point to a concentrated customer base — G42 and MBZUAI make up a large share of revenue — plus intensifying competition from Nvidia's LPX rack and a fast-inference market that remains niche. The stock is up 7% on the week but still down 12% over the past month, so the analyst community is chasing a stock that is recovering from a rough stretch.
The lending market tells a story that runs in a very different direction. Availability has been at zero for two consecutive sessions — every share in the pool is lent out, and no new short positions can be opened regardless of demand. That reading matches the tightest level seen since listing. Short interest climbed another 1.8% on Tuesday to 11.6 million shares, up 18% on the week and roughly six times the 1.9 million level that held through most of May. Cost to borrow more than doubled over the week to just under 2%, a sharp reversal from the 0.79% trough recorded in mid-June. The ORTEX short score ticked up to 68.4, its highest reading in the data window. The setup is one where shorts have already built their position and are now trapped — they cannot easily add, and with availability at zero they cannot easily cover by finding fresh borrows for someone else to step in opposite.
Options positioning has shifted in parallel. The put/call ratio rose to 0.72 on Tuesday, the highest reading in several weeks and now running above the 20-day average of 0.69. That is a modest elevation — well below the 0.92 high from late May — and the z-score of 0.30 does not signal unusual hedging pressure. The direction of travel is worth noting: the PCR had been falling steadily from late May through mid-June as the stock recovered, and this week's uptick coincides with the post-earnings pop. Investors appear to be locking in some gains via puts after the stock's move rather than making a directional bet.
Institutional ownership is heavily concentrated in venture and growth hands, with FMR (Fidelity) the largest holder at 11.6% of shares. Foundation Capital, Benchmark, and Eclipse Operations each hold between 6% and 7%. The insider register shows a cluster of May 13 sales at $185 — CEO Andrew Feldman sold $19.8 million worth, COO Dhiraj Mallick sold $90.9 million, and CTO Sean Lie sold $17.8 million. Those sales were made at prices well below the current level of $226, which limits their signalling value as bearish conviction. Earnings history is thin, but the June 12 print produced a 1-day decline of 3.8% before the stock recovered to nearly flat over five days.
The next scheduled earnings event is September 22. Between now and then, the key variable to watch is whether availability at zero produces any meaningful covering activity or whether the borrow pool simply stays fully deployed — because without available shares entering the market, the short position cannot grow further and any catalyst forcing covering has nowhere to source stock.
See the live data behind this article on ORTEX.
Open CBRS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
